About: Community‐acquired respiratory virus lower respiratory tract disease in allogeneic stem cell transplantation recipient: Risk factors and mortality from pulmonary virus‐bacterial mixed infections

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Community‐acquired respiratory virus lower respiratory tract disease in allogeneic stem cell transplantation recipient: Risk factors and mortality from pulmonary virus‐bacterial mixed infections Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : covidontheweb.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	Community‐acquired respiratory virus lower respiratory tract disease in allogeneic stem cell transplantation recipient: Risk factors and mortality from pulmonary virus‐bacterial mixed infections
Creator	Navarro, David Giménez, Estela Solano, Carlos Moles, Paula Salavert, Miguel Sanz, Guillermo Sanz, Jaime Calabuig, Marisa Madrid, Silvia Carlos Hernández-Boluda, Juan Dolores Gómez, María Luis Piñana, José María González, Eva Ariadna Pérez, \| Aitana Balaguer-Roselló, \| Montoro, \| Víctor Vinuesa, \|
Source	Medline; PMC
abstract	Risk factors (RFs) and mortality data of community‐acquired respiratory virus (CARVs) lower respiratory tract disease (LRTD) with concurrent pulmonary co‐infections in the setting of allogeneic hematopoietic stem cell transplantation (allo‐HSCT) is scarce. From January 2011 to December 2017, we retrospectively compared the outcome of allo‐HSCT recipients diagnosed of CARVs LRTD mono‐infection (n = 52, group 1), to those with viral, bacterial, or fungal pulmonary CARVs LRTD co‐infections (n = 15, group 2; n = 20, group 3, and n = 11, group 4, respectively), and with those having bacterial pneumonia mono‐infection (n = 19, group 5). Overall survival (OS) at day 60 after bronchoalveolar lavage (BAL) was significantly higher in group 1, 2, and 4 compared to group 3 (77%, 67%, and 73% vs 35%, respectively, P = .012). Recipients of group 5 showed a trend to better OS compared to those of group 3 (62% vs 35%, P = .1). Multivariate analyses showed bacterial co‐infection as a RF for mortality (hazard ratio[HR] 2.65, 95% C.I. 1.2‐6.9, P = .017). We identified other 3 RFs for mortality: lymphocyte count <0.5 × 10(9)/L (HR 2.6, 95% 1.1‐6.2, P = .026), the occurrence of and CMV DNAemia requiring antiviral therapy (CMV‐DNAemia‐RAT) at the time of BAL (HR 2.32, 95% C.I. 1.1‐4.9, P = .03), and the need of oxygen support (HR 8.3, 95% C.I. 2.9‐35.3, P = .004). CARV LRTD co‐infections are frequent and may have a negative effect in the outcome, in particular in the context of bacterial co‐infections.
has issue date	2018-06-22(xsd:dateTime)
bibo:doi	10.1111/tid.12926
bibo:pmid	29809298
has license	no-cc
sha1sum (hex)	79aca6ecc85195d85ab35ca9b11cdcca4a769545
schema:url	https://doi.org/10.1111/tid.12926
resource representing a document's title	Community‐acquired respiratory virus lower respiratory tract disease in allogeneic stem cell transplantation recipient: Risk factors and mortality from pulmonary virus‐bacterial mixed infections
has PubMed Central identifier	PMC7169706
has PubMed identifier	29809298
schema:publication	Transpl Infect Dis
resource representing a document's body	covid:79aca6ecc85195d85ab35ca9b11cdcca4a769545#body_text
is schema:about of	named entity 'infection' named entity 'CMV' named entity 'RFs' named entity 'allogeneic hematopoietic stem cell transplantation' named entity 'HSCT' named entity 'bronchoalveolar lavage' named entity 'HR 2' named entity 'hazard ratio' named entity 'Multivariate analyses' named entity 'lower respiratory tract' named entity 'virus' named entity 'Risk factors' named entity 'CMV' named entity 'HSCT' named entity 'viruses' named entity 'bacterial pneumonia' named entity 'multivariate analysis' named entity 'coinfections' named entity 'ISI' named entity 'influenza virus' named entity 'gram-negative bacteria' named entity 'co-infection' named entity 'diagnostic tools' named entity 'immunoglobulin' named entity 'HSCT' named entity 'clinical practice' named entity 'ISI' named entity 'virus' named entity 'virus' named entity 'oxygen' named entity 'HSCT' named entity 'infection' named entity 'clinical outcome' named entity 'neutropenia' named entity 'B-cell' named entity 'RFs' named entity 'CMV' named entity 'co-infection' named entity 'HPiV' named entity 'quantitation' named entity 'pathogens' named entity 'RT-PCR' named entity 'bronchoalveolar lavage' named entity 'HSCT' named entity 'HSCT' named entity 'co-infection' named entity 'pathogens' named entity 'ISI' named entity 'assay' named entity 'RFs' named entity 'bacteremia' named entity 'ISI' named entity 'lower respiratory tract' named entity 'RT-PCR' named entity 'Bacterial pneumonia' named entity 'co-infection' named entity 'CMV' named entity 'radiology' named entity 'co-infection' named entity 'RSV' named entity 'CMV' named entity 'RT-PCR' named entity 'immunosuppression' named entity 'infusion' named entity 'Bronchoscopy'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software